Ketamine booster for shock therapy? new trial aims to lift depression and protect memory

NCT ID NCT07088380

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding a low dose of ketamine to electroconvulsive therapy (ECT) can better relieve depression and reduce memory problems in people with treatment-resistant major depressive disorder. Thirty hospitalized adults will receive either ketamine or a placebo during three ECT sessions. Researchers will measure changes in depression symptoms, suicidal thoughts, and anxiety over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ketamine hydrochloride
What this could lead to
If it works, this could point toward a more effective and less mentally foggy way to treat severe depression that hasn't responded to other treatments.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Ketamine can cause side effects like dizziness or dissociation, and the added benefit over ECT alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IRCCS Ospedale San Raffaele Turro

    RECRUITING

    Milan, 20127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.